Heme oxygenase-1 and 2 common genetic variants and risk for restless legs syndrome by García Martín, Elena et al.
icine®
ONAL STUDYMed
OBSERVATIHeme Oxygenase-1 and 2 Common Genetic
Variants and Risk for Restless Legs Syndrome
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Abstract: Several neurochemical, neuropathological, neuroimaging,
and experimental data, suggest that iron deficiency plays an important
role in the pathophysiology of restless legs syndrome (RLS). Heme-
oxygenases (HMOX) are an important defensive mechanism against
oxidative stress, mainly through the degradation of heme to biliverdin,
free iron, and carbon monoxide. We analyzed whether HMOX1 and
HMOX2 genes are related with the risk to develop RLS.
We analyzed the distribution of genotypes and allelic frequencies of
the HMOX1 rs2071746, HMOX1 rs2071747, HMOX2 rs2270363, ando, MD, Belén Pilo-d D, PhD,
a, MD, PhD, and José A.G. Agúndez, MD, PhD
The frequencies of rs2071746TT genotype and rs2071746T allelic
variant were significantly lower in RLS patients than that in controls,
although the other 3 studied SNPs did not differ between RLS patients
and controls. None of the studied polymorphisms influenced the disease
onset, severity of RLS, family history of RLS, serum ferritin levels, or
response to dopaminergic agonist, clonazepam or GABAergic drugs.
The present study suggests a weak association between HMOX1
rs2071746 polymorphism and the risk to develop RLS in the Spanish
population.
(Medicine 94(34):e1448)
Abbreviations: CNVs = copy number variations, DNA =
deoxyribonucleic acid, ET = Essential tremor, GABA = gamma-
hydroxybutyric acid, HMOX = Heme-oxygenase, HO = Heme-
oxygenase, HSP = Heat Shock Protein, IRLSSGRS = International
Restless Legs Syndrome Study Group Rating Scale, PD = Parkinson’s
disease, qPCR = Real-time quantitative polymerase chain reaction,
RLS = Restless legs syndrome, RNA = Ribonucleic acid, RR =
Relative risk, SNP = single nucleotide polymorphism, VNTR =
Variable number tandem repeats, WED = Willis Ekbom Disease.
INTRODUCTION
D espite there are many data supporting the role of geneticfactors in the aetiology and the pathogenesis of restless
legs syndrome (RLS), also called Willis–Ekbom disease
(WED), such as the high frequency of family history of RLS
reported by patients with this syndrome, data found in family
studies, and the higher concordance rates in monozygotic twins
when compared with dizygotic ones, the identification of the
responsible gene(s) remains to be clarified (revised in reference).1
The pathophysiology of idiopathic RLS is not well estab-
lished. Although recent reports suggest the possible role of
several neurotransmitters and/or neuromodulators such as
aspartate, gamma-hydroxybutyric acid (GABA), glutamate
and opiates, and a possible relation with vitamin D deficiency,
the main hypotheses (likely interconnected) are dopaminergic
dysfunction and iron deficiency (revised in reference).2
Heme oxygenase is an essential enzyme in heme catabo-
lism, and it occurs as 2 main isozymes, an inducible heme
oxygenase-1 (HMOX1) and a constitutive heme oxygenase-2
(HMOX2), which are encoded by the genes designated, respect-
ively, as HMOX1, HO-1 or HSP32 (gene identity 3162, chromo-
some 22q13.1) and HMOX2 or HO-2 (gene identity 3163,
chromosome 16p13.3). Several recent studies have shownertain single nucleotide polymorphisms
–6 and HMOX25,7 genes and the risk for
D)3–5,7 and for essential tremor (ET).6
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Because of the important role of brain iron deficiency in
RLS, suggested by neuropathological, transcranial sonography,
neuroimaging, and experimental data, it seems reasonable to
study the possible association between SNPs related with iron
metabolism and the risk for RLS. With the aim to investigate a
possible association between HMOX1 and HMOX2 polymorph-
isms and the risk of developing RLS, we genotyped HMOX1




We studied 205 unrelated patients diagnosed with idio-
pathic RLS according to established RLS diagnostic criteria,8,9
and 445 gender-matched controls. Demographic data of both
series are summarized in Table 1. Recruitment and diagnosis of
RLS patients was carried out by consultant neurologists with
expertise in Movement Disorders belonging to the Movement
Disorders Units of 5 Hospitals. Inclusion criteria, besides the
diagnosis of idiopathic RLS, were the absence of other previous
neurological diseases, and the exclusion of possible causes of
secondary RLS such as anaemia, renal failure, rheumatoid
arthritis, peripheral neuropathy, and exposure to neuroleptics,
antidepressants, or other drugs able to induce or to aggravate
RLS. For this purpose, all patients underwent laboratory studies
(blood count, routine biochemistry, iron metabolism studies,
serum levels of vitamin B12, folic acid, and thyroid hormones,
proteinogram, antinuclear antibodies, rheumatoid factor, and
nerve conduction studies). The International RLS Study Group
Rating Scale (IRLSSGRS)10 was used to assess RLS severity.
Positive family history of RLS was reported by 115
patients, 46 had ferritin levels between 30 and 50 ng/ml and
157 >50 ng/ml. Regarding previous treatments 159 have
received dopamine agonists, 59 clonazepam, and 34 gabapentin
or pregabaline, either alone or in combination.
The 445 controls were healthy Caucasian Spanish indi-
viduals matched by gender (275 of then were recruited from the
Clı́nica Universitaria de Navarra, Pamplona, Spain; and the
remaining 270 were recruited at the Infanta Cristina University
Hospital, Badajoz, Spain). None of the controls had RLS,
tremor, or other movement disorders.
Garcı́a-Martı́n et alEthical Aspects
All the participants included in the study gave their written
informed consent after full explanation of the procedure. The








53.8 (15.0) 63.6 (14.6)




Female, % 170 (82.9%) 369 (82.9%)
NA¼ not applicable, RLS¼ restless legs syndrome, SD¼ standard
deviation.
2 | www.md-journal.comEthics Committees of Clinical Investigation of the Province of
Cáceres (Cáceres, Spain), University Hospital ‘‘Prı́ncipe de
Asturias’’ (University of Alcalá, Alcalá de Henares, Madrid,
Spain), the Infanta Cristina University Hospital (Badajoz,
Spain), and Clı́nica Universitaria de Navarra (Pamplona, Spain)
approved the study that was conducted according to the prin-
ciples enumerated in the Helsinki Declaration of 1975. Most of
the patients recruited had participated in other previous studies
of genetic association with RLS risk.11–14
Genotyping
Two single nucleotide polymorphisms in the HMOX1 gene
and two polymorphisms in the HMOX2 gene were studied by
means of TaqMan probes. Analyses included the HMOX1 SNP
rs2071746 (an upstream variant), HMOX1 rs2071747 (a mis-
sense mutation within the exon 1 of the HMOX1 gene), the SNP
rs2270363 (a polymorphism in the regulatory region of the
human HMOX2 gene), and rs1051308 (a polymorphism in the
30untranslated region). The selection of these SNPs was done
because of their putative functional effects and their expected
allele frequency in Caucasian individuals.5,7
Genotyping performed in genomic DNA from venous blood
samples of participants and was carried out using TaqMan assays
(Applied Biosciences Hispania, Alcobendas, Madrid, Spain)
designed to detect the four previously mentioned SNPs desig-
nated respectively by the supplier with the following part num-
bers: C__15869717_10, C__22272778_10, C__15957370_10
and C___9695078_1_. An Eppendorf realplex thermocycler,
using fluorescent probes, was used for the detection by qPCR.
The amplification conditions were the following: after a dena-
turation time of 10 min at 96 8C, 45 cycles of 92 8C 15 s and 60 8C
90 s were carried out and fluorescence was measured at the end
of each cycle and at endpoint. Determinations were done by
triplicate in all samples, and then genotypes were assigned
both using a gene identification software (RealPlex 2.0, Eppen-
dorf) and analysing the reference cycle number for each fluor-
escence curve, calculated by means of the CalQPlex algorithm
(Eppendorf).
The TaqMan copy number assays Hs00774483_cn and
Hs01223070_cn, respectively, were used for the analysis of
copy number variations (CNVs) of the HMOX1 and HMOX2
genes. Both assays were designed to hybridize within the open
reading frame in the target genes (Applied Biosciences Hispa-
nia, Alcobendas, Madrid, Spain). An Applied Biosystems 7500
real-time thermocycler using as a copy number reference assay
RNAse P was used to carry out the amplification, as described
by the manufacturer. All reactions were carried out in quad-
ruplicate. The analysis of the results were performed using the
CopyCaller Software (Applied Biosciences Hispania). Accord-
ing to standard procedures in CNV analyses, we designed as
heterozygous (null/present) those samples with a single copy of
the corresponding gene. As the probes were designed to detect
exonic sequences, even if the rest of the gene would remain in
these so-called null alleles, the translated protein would not
be functional.
Statistical Analysis
The DeFinetti program (http://ihg.gsf.de/cgi-bin/hw/
hwa1.pl) was used to analyze the Hardy–Weinberg equilibrium,
the PLINK software15 to perform the allelic and genotype
Medicine  Volume 94, Number 34, August 2015analyses, and the program PHASE v2.1.116 to perform haplo-
type reconstruction using the default model for recombination
rate variation with 1000 iterations, 500 burn-in iterations, and a
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. HMOX Genotypes and Allelic Variants of Patients with RLS and Healthy Volunteers. The Values in Each Cell Represent





(n¼ 445,888 alleles) OR (95% CI), P; NPV (95% CI)
HMOX1 rs2071746 A/A 70 (34.1; 27.7–40.6) 120 (27.0; 22.8–31.1) 1.40 (0.97–2.04); 0.062; 0.71 (0.68–0.73)
A/T 105 (51.2; 44.4–58.1) 221 (49.7; 45.0–54.3) 1.06 (0.75–1.50); 0.712; 0.69 (0.65–0.73)
T/T 30 (14.6; 9.8–19.5) 102 (22.9; 19.0–26.8) 0.58 (0.36–0.92); 0.015; 0.66 (0.65–0.68)
Null/A 0 (–) 2 (0.4; 0.2–1.1) 0.0 (0.0–8.44); 0.337; 0.68 (0.68–0.69)
Null/T 0 (–) 0 (–) –
HMOX1 rs2071747 G/G 192 (93.7; 90.3–97.0) 404 (90.8; 88.1–93.5) 1.50 (0.76–3.02); 0.218; 0.76 (0.63–0.86)
G/C 13 (6.3; 3.0–9.7) 38 (8.5; 5.9–11.1) 0.73 (0.36–1.45); 0.333; 0.68 (0.67–0.69)
C/C 0 (0.0; 0.0–0.0) 1 (0.2; 0.2–0.7) 0.0 (0.0–18.8); 0.337; 0.52 (0.52–0.52)
Null/G 0 (–) 2 (0.4; 0.2–1.1) 0.0 (0.0–4.41); 0.174; 0.52 (0.52–0.52)
Null/C 0 (–) 0 (–) –
HMOX2 rs2270363 G/G 107 (52.2; 45.4–59.0) 211 (47.4; 42.8–52.1) 1.21 (0.86–1.71); 0.258; 0.71 (0.67–0.74)
G/A 78 (38.0; 31.4–44.7) 189 (42.5; 37.9–47.1) 0.83 (0.58–1.18); 0.287; 0.67 (0.64–0.70)
A/A 20 (9.8; 5.7–13.8) 43 (9.7; 6.9–12.4) 1.01 (0.56–1.82); 0.970; 0.69 (0.67–0.70)
Null/G 0 (–) 2 (0.4; 0.2–1.1) 0.0 (0.0–4.41); 0.174; 0.52 (0.52–0.52)
Null/A 0 (–) 0 (–) –
HMOX2 rs1051308 A/A 97 (47.3; 40.5–54.2) 188 (42.2; 37.7–46.8) 1.23 (0.87–1.74); 0.226; 0.70 (0.67–0.74)
A/G 84 (41.0; 34.2–47.7) 197 (44.3; 39.7–48.9) 0.87 (0.62–1.24); 0.431; 0.67 (0.64–0.71)
G/G 24 (11.7; 7.3–16.1) 58 (13.0; 9.9–16.2) 0.89 (0.52–1.51); 0.636; 0.68 (0.67–0.70)
Null/A 0 (–) 1 (0.2; 0.2–0.7) 0.0 (0.0–18.8); 0.337; 0.52 (0.52–0.52)
Null/G 0 (–) 1 (0.2; 0.2–0.7) 0.0 (0.0–18.8); 0.337; 0.52 (0.52–0.52)
Alleles
HMOX1 rs2071746 A 245 (59.8; 55.0–64.5) 463 (52.1; 48.9–55.4) 1.37 (1.07–1.74); 0.010; 0.72 (0.69–0.75)
T 165 (40.2; 35.5–45.0) 425 (47.9; 44.6–51.1) 0.73 (0.58–0.94); 0.010; 0.65 (0.63–0.68)
HMOX1 rs2071747 G 397 (96.8; 95.1–98.5) 848 (95.5; 94.1–96.9) 1.44 (0.74–2.87); 0.259; 0.76 (0.62–0.86)
C 13 (3.2; 1.5–4.9) 40 (4.5; 3.1–5.9) 0.69 (0.34–1.36); 0.259; 0.68 (0.68–0.69)
HMOX2 rs2270363 G 292 (71.2; 66.8–75.6) 613 (69.0; 66.0–72.1) 1.11 (0.85–1.45); 0.425; 0.70 (0.66–0.74)
A 118 (28.8; 24.4–33.2) 275 (31.0; 27.9–34.0) 0.90 (0.69–1.17); 0.425; 0.68 (0.66–0.70)
HMOX2 rs1051308 A 278 (67.8; 63.3–72.3) 574 (64.6; 61.5–67.8) 1.15 (0.89–1.49); 0.265; 0.70 (0.67–0.74)
G 132 (32.2; 27.7–36.7) 314 (35.4; 32.2–38.5) 0.87 (0.67–1.12); 0.265; 0.67 (0.66–0.69)
Null HMOX1 0 (–) 2 (0.2; 0.1–0.5) 0.00 (0.00–8.80); 0.336; 0.68 (0.68–0.68)
Null HMOX2 0 (–) 2 (0.2; 0.1–0.5) 0.00 (0.00–8.80); 0.336; 0.68 (0.68–0.68)
CI¼ confidence interval, NPV¼ negative predictive value, OR¼ odds ratio, RLS¼ restless legs syndrome.
Medicine  Volume 94, Number 34, August 2015 Heme Oxygenase Genes and Restless Legs Syndromethinning interval of 1 was used. Diplotypes were obtained from
the combination of haplotypes in the best run (the one that
showed the maximum consistency of results across all runs.17
Statistical analyses were performed using the SPSS 19.0 for
Windows (SPSS Inc, Chicago, IL). We calculated intergroup
comparison values by means of the x2 or Fisher tests when
appropriate, and calculated the 95% confidence intervals as
well. The False discovery rate procedure18 was used to calculate
correction for multiple testing (Pc values).
The determination of the sample size was done from
variant allele frequencies observed in control individuals with
a genetic model analyzing the frequency for carriers of the
disease gene with a RR value¼ 1.5 (P¼ 0.05). The statistical
power for 2-tailed associations for the presence of the SNPs
identified in this study (rs2071746, rs2071747, rs2270363 and
rs1051308) was 95.06%, 38.51%, 92.72% and 94.23%, respect-
ively. The Breslow–Day test was used to analyze testing for
heterogeneous association (homogeneity test).The negative predictive value (NPV) was calculated as d/r2
(d¼ number of control individuals with the risk factor absent;
r2¼ sum of patients and controls with the risk factor absent).19
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.RESULTS
The frequencies of the rs2071746, rs2071747, rs2270363,
and rs1051308 genotypes and allelic variants were in Hardy–
Weinberg’s equilibrium, both in RLS patient and control groups
(Table 2). None of the patients and only 2 control individuals
carried a single copy of the HMOX1 and HMOX2 genes, and
hence CNVs were not further considered as major putative risk
factors. The frequencies of rs2071746TT genotype and
rs2021746T allele were significantly lower in RLS patients
than in controls, both in the whole series (Table 2) and in female
gender (Table 3). These differences remained significant for the
rs2071746 allele frequency after multiple comparison analysis
according to the false discovery rate correction. The frequencies
of rs2071747, rs2270363, and rs1051308 did not differ signifi-
cantly between RLS patient and control groups.
MeanþSD age at the onset of RLS did not differ
between RLS patients carrying the genotypes rs2071746AA,
rs2071746AT, and rs2071746TT (44.4 16.6, 43.2 17.9, and
44.4 16.6 years, respectively); genotypes rs2071747GG and
rs2071747GC (43.6 17.0 and 43.8 15.4 years, respectively);

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Garcı́a-Martı́n et al Medicine  Volume 94, Number 34, August 2015
4 | www.md-journal.com Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
(43.4 17.6, 44.2 16.8, and 42.3 13.1 years, respectively);
and genotypes rs1051308AA, rs1051308AG, and rs1051308AA
(42.9 17.3, 45.0 17.1, and 41.6 14.5 years, respectively).
Meanþ SD IRLSSGRS scores were similar for RLS
patients carrying genotypes rs2071746AA, rs2071746AT, and
rs2071746TT (24.6 7.0, 25.02 6.0, and 23.3 8.0, respect-
ively); genotypes rs2071747GG and rs2071747GC (24.8 6.5
and 21.7 6.4, respectively); genotypes rs2270363GG,
rs2270363GA, and rs2270363AA (24.6 6.8, 24.7 6.6, and
22.7 6.9, respectively); and genotypes rs1051308AA, r-
s1051308AG, and rs1051308AA (24.8 6.7, 23.8 6.6, and
23.8 6.8, respectively).
The distribution of genotypes and allelic frequencies was
similar in RLS patients with positive family history of RLS than
in those with negative family history of RLS (Table 4), RLS
patients with relatively low serum levels of ferritin (30–50 ng/
ml) versus those with serum ferritin levels> 50 ng/ml (Table 4),
and those RLS patients in which RLS symptoms improved with
dopamine agonists, clonazepam, or gabapentin/pregabaline
therapy compared with those who did not improve with these
drugs (Table 5).
DISCUSSION
Family reports of RLS are usually consistent with an
autosomal dominant pattern of inheritance, although families
with recessive or non-mendelian patterns have been described
as well. To date, linkage studies have identified at least 8 genes/
loci (most of them apparently autosomal dominant) in families
with RLS. Association between several variants of MEIS1
(closely related with iron metabolism),20 PTPRD, and BTBD9
genes and with the risk of developing RLS has been found in
genome wide association studies (GWAS),1 whereas PCDHA3
gene has been found to be related with the development of RLS
in a large German family by using exome sequencing studies.1
Case-control association studies in RLS are scarce and incon-
clusive (revised in).1
Data from the present case-control association study
suggest a weak association between the allelic variant HMOX1
rs2071746T, but not of the other 3 studied SNPs in the HMOX,
and the risk for RLS. However, none of the studied SNPs were
related with the age at onset or severity of RLS, positivity of
family history or RLS, serum ferritin levels, and response to
several treatments. The lack of relation between SNPs in the
HMOX gene and serum ferritin levels is on the line of a previous
study by Oexle et al,21 that described that SNPs at the known
RLS loci and iron-related genes did not significantly affect
serum iron parameters in several cohorts.
We have previously reported association between
HMOX1 rs2071746T variant and the risk for PD and ET,5,6
suggesting a possible link between these diseases. However,
how this SNP might change HMOX transcription both in PD
(associated with elevated iron content) and RLS (associated
with iron deficiency), and the possible putative mechanisms
suggesting an association between HMOX and RLS could be
speculative. So far there are no clues on putative biological
mechanisms underlying the association found. The rs2071746
SNP is located in the 50 area, 500 bp before the coding area,
and therefore the most likely mechanism would be related to
Medicine  Volume 94, Number 34, August 2015gene expression. The area where the SNP is located has several
transcription factor binding sites. One of these, designated as
CUTL1 [T00100] is present in the wild-type sequence, but
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.disappears in the mutated sequence. The disruption of this
transcription factor-binding site may underlie differences in
gene expression.
In the brain, the HMOX pathway is a very important
defensive mechanism against oxidative stress, mainly through
the degradation of heme to biliverdin, free iron, and carbon
monoxide. Moreover, an up-regulation of HMOX1 expression
(resulting in increase of oxidative stress and sequestration of
iron non-linked to transferrin in the mitochondrial department)
has been found in the brains of patients with PD, Alzheimer’s
disease, and multiple sclerosis.22,23
Despite the pathophysiology of RLS is not well-estab-
lished, it has been suggested an important role of iron
deficiency in the pathogenesis of idiopathic RLS.1 Most of
the magnetic resonance imaging studies found decreased iron
content,24–28 and transcranial ultrasonography studies hypoe-
chogenicity (reflecting decreased iron as well),29–31 in the
substantia nigra of RLS patients compared with controls.
Moreover, neuropathological studies have found decreased
concentrations of iron, ferritin, and other proteins related with
iron homeostasis in the substantia nigra of RLS patients.32–36
The results of studies assessing cerebrospinal fluid and serum/
plasma levels of iron, ferritin, and transferrin are controversial
(revised in).2 Several data in experimental models resembling
RLS suggest an important interaction between iron deficiency
and the dopaminergic system in the pathogenesis of RLS
(revised in).2
To our knowledge, HMOX1 and HMOX2 expression has
not been measured in neuropathological studies of RLS patients
yet. It could be proposed that if the iron content is decreased in
the substantia nigra of RLS patients, HMOX should act as
protective against iron-related oxidative stress, and alterations
in HMOX1 and HMOX2 genes could be related with the iron
deficiency model of the pathogenesis of RLS.
A limitation of the present study is that, whereas 3 SNPs had
a high statistical power, the other one, designated as rs2071747,
had not. However, rs207174 is an allele with a very low minor
frequency (MAF) in healthy Europeans (0.045 in this study and
0.060 in the 1000 genomes database). Such SNP is also very rare
in other human populations, MAF ranging from 0.020 to 0.050
(http://browser.1000genomes.org/Homo_sapiens/Variation/
Population?db¼ core;r¼ 22:35776685–35777685;v¼ rs2071747;
vdb¼ variation;vf¼ 1641286). To obtain a reliable statistical
power for such SNP with the RR value¼ 1.5 (P¼ 0.05), the
minimum sample size is estimated to be 1900 case-control
pairs. However, it should be stressed that the significant
findings in this study are related to another SNP that has a
high statistical power: rs2071746 has a power equal to 95.6%.
Another potential limitation should be a selection bias.
Although it is well known that in epidemiological studies the
male-to-female ratios of incidence rate of RLS are in the range
of 1:1.5 to 1:2.0 in adult populations, the male-to-female ratio of
RLS patients is1:5. This proportion is likely to be related with
the fact that the recruitment of patients was done in a clinical
(hospital-based) setting.
Although the results of the present study should be taken
with caution because of the previously discussed limitations,
and deserve further replication studies in other populations,
Heme Oxygenase Genes and Restless Legs Syndromethey suggest a slightly decreased risk for RLS in Spanish
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